The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease

Objective. Metabolic bone disease (MBD) and muscle wasting (MW) are serious complications in adult patients suffering from inflammatory bowel disease. These complications may be caused by alterations in the insulin-like growth factor (IGF) system. The aim of the present study was to assess changes i...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2007, Vol.42 (4), p.464-470
Main Authors: Eivindson, Martin, Grønbæk, Henning, Skogstrand, Kristin, Thorsen, Poul, Frystyk, Jan, Flyvbjerg, Allan, Dahlerup, Jens F.
Format: Article
Language:English
Subjects:
Adult
Anti-Inflammatory Agents - therapeutic use
Antibodies, Monoclonal - therapeutic use
Biological and medical sciences
C-Reactive Protein - analysis
Crohn Disease - blood
Crohn Disease - drug therapy
Crohn's disease
Crohn's Disease Activity Index
Cytokines - blood
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastrointestinal Agents - therapeutic use
Harvey-Bradshaw Index
Humans
IGF-I
IGF-II
IGFBP-1
IGFBP-2
IGFBP-3
Immunomodulators
Inflammation Mediators - blood
Infliximab
Insulin-Like Growth Factor Binding Protein 1 - blood
Insulin-Like Growth Factor I - analysis
Insulin-Like Growth Factor II - analysis
Male
Medical sciences
Orosomucoid - analysis
Other diseases. Semiology
Pharmacology. Drug treatments
Serum Albumin - analysis
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. Metabolic bone disease (MBD) and muscle wasting (MW) are serious complications in adult patients suffering from inflammatory bowel disease. These complications may be caused by alterations in the insulin-like growth factor (IGF) system. The aim of the present study was to assess changes in the IGF system in patients with active Crohn's disease (CD) before and during infliximab treatment. Material and methods. We studied 13 patients with therapy refractory CD, treated with infliximab (5 mg/kg body-weight) at baseline and after 2 weeks. The IGF system and markers of inflammation were examined at baseline, on days 2-5 and after 1, 4, and 8 weeks. Ten healthy age- and gender-matched persons served as controls. Results. Total IGF-I and IGF binding protein (IGFBP)-3 levels were reduced by 36% (p
ISSN:0036-5521
1502-7708
DOI:10.1080/00365520601010115